Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Endocrinological Investigation
Erschienen in: Journal of Endocrinological Investigation 1/2016

01.01.2016 | Consensus Statement

Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

verfasst von: A. Stigliano, I. Chiodini, R. Giordano, A. Faggiano, L. Canu, S. Della Casa, P. Loli, M. Luconi, F. Mantero, M. Terzolo

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

The rarity (0.5–2 cases per million per year) and aggressiveness of adrenocortical carcinoma (ACC) have limited our knowledge of the biological processes underlying its development and the design of specific and effective therapies. ACC is often associated to poor prognosis, with a mean 5-year survival rate between 16 and 47 %, dramatically dropping to 5–10 % in metastatic disease. Prognosis mainly depends on tumor stage and feasibility of radical surgery. At present, complete surgical removal of the tumor, possibly associated to adjuvant mitotane therapy, represents the best treatment option for ACC. Treatment of advanced ACC remains disappointing for limited efficacy and significant toxicity [1‐3]. …
Literatur
1.
Fassnacht M, Libé R, Kroiss M et al (2011) Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 7:323–335PubMedCrossRef
2.
3.
Swiglo BA, Murad MH, Schünemann HJ et al (2008) A case for clarity, consistency, and helpfulness: state of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metabol 93:666–673CrossRef
4.
Fassnacht M, Kenn W, Allolio B (2004) Adrenal tumors: how to establish malignancy? J Endocrinol Invest 27:387–399PubMedCrossRef
5.
Tauchmanova L, Colao A, Marzano LA et al (2004) Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 28:896–903PubMedCrossRef
6.
Arlt W, Biehl M, Taylor AE et al (2011) Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 96:3775–3784PubMedPubMedCentralCrossRef
7.
Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 93:1526–1540CrossRef
8.
Terzolo M, Bovio S, Pia A et al (2009) Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metabol 23:233–243CrossRef
9.
Chiodini I (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236PubMedCrossRef
10.
Terzolo M, Pia A, Reimondo G (2012) Subclinical Cushing’s syndrome: definition and management. Clin Endocrinol 76:12–18CrossRef
11.
Vassiliadi DA, Tsagarakis S (2011) Endocrine incidentalomas––challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol 7:668–680PubMedCrossRef
12.
Terzolo M, Stigliano A, Chiodini I et al (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164:851–870PubMedCrossRef
13.
Morelli V, Masserini B, Salcuni AS et al (2010) Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol 73:161–166
14.
Eller-Vainicher C, Morelli V, Salcuni AS et al (2010) Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur J Endocrinol 163:925–935PubMedCrossRef
15.
Seccia TM, Fassina A, Nussdorfer G et al (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. End Relat Cancer 12:149–159CrossRef
16.
Fischer E, Beuschlein F, Bidlingmaier M, Reincke M (2011) Commentary on the Endocrine Society Practice Guidelines: consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 12:43–48PubMedCrossRef
17.
Funder JW, Carey RM, Fardella C et al (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:3266–3281PubMedCrossRef
18.
Libè R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13–28PubMedCrossRef
19.
Terzolo M, Alì A, Osella G et al (2000) The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol 142:611–617PubMedCrossRef
20.
Lenders JWM, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocr Metab 99:1915–1942PubMedCrossRef
21.
Fishman EK, Deutch BM, Hartman DS et al (1987) Primary adrenocortical carcinoma: CT evaluation with clinical correlation. AJR 148:531–535PubMedCrossRef
22.
Zhang HM, Perrier ND, Grubbs EG et al (2012) CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol 67:38–46PubMedPubMedCentralCrossRef
23.
Park BK, Kim CK, Kwon GY et al (2007) Re-evaluation of pheochromocytomas on delayed contrast enhanced CT: washout enhancement and other imaging features. Eur Radiol 17:2804–2809PubMedCrossRef
24.
25.
Terzolo M, Ali A, Osella G et al (1997) Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg 132:914–919PubMedCrossRef
26.
Lee MJ, Hahn PF, Papanicolau N et al (1991) Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 179:415–418PubMedCrossRef
27.
Boland GW, Lee MJ, Gazelle GS et al (1998) Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR 171:201–204PubMedCrossRef
28.
Blake MA, Kalra MK, Sweeney A et al (2006) Distinguishing benign from malignant adrenal masses: multidetector row CT protocol with 10-minute delay. Radiology 238:578–585PubMedCrossRef
29.
30.
Petersenn S, Richter PA, Broemel T et al (2015) Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrin 172:415–422CrossRef
31.
Korobkin M, Brodeur FJ, Francis IR et al (1998) CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170:747–752PubMedCrossRef
32.
Peña CS, Boland GW, Hahn PF et al (2000) Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217:798–802PubMedCrossRef
33.
Caoili EM, Korobkin M, Francis IR et al (2002) Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222:629–633PubMedCrossRef
34.
Szolar DH, Korobkin M, Reittner P et al (2005) Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 234:479–485PubMedCrossRef
35.
Sangwaiya MJ, Boland JW, Cronin CG et al (2010) Incidental adrenal lesions: accuracy of characterization with contrast-enhanced washout multidetector CT-10-minute delayed imaging protocol revisited in a large patient cohort. Radiology 256:504–510PubMedCrossRef
36.
Chiche L, Dousset B, Kieffer E, Chapuis Y (2006) Adrenocortical carcinoma extending into the inferior vena cava: Presentation of a 15-patient series and review of the literature Surgery 139:15–27
37.
Park BK, Kim CK, Kim B, Lee JH (2007) Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology 243:760–765PubMedCrossRef
38.
Ferrozzi F, Bova D (1995) CT and MR demonstration of fat within an adrenal cortical carcinoma. Abdom Imaging 20:272–274PubMedCrossRef
39.
Heye S, Woestenborghs H, Van Kerkhove F et al (2005) Adrenocortical carcinoma with fat inclusion: case report. Abdom Imaging 30:641–643PubMedCrossRef
40.
Marin D, Soher BJ, Dale BM et al (2010) Characterization of adrenal lesions: comparison of 2D and 3D dual gradient-echo MR imaging at 3 T-preliminary results. Radiology 254:179–184PubMedCrossRef
41.
Faria JF, Goldman SM, Szejnfeld J et al (2007) Adrenal masses: characterization with in vivo proton MR spectroscopy—initial experience. Radiology 245:788–797PubMedCrossRef
42.
Boland GW, Dwamena BA, Sangwaiya MJ et al (2011) Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259:117–126PubMedCrossRef
43.
Leboulleux S, Dromain C, Bonniaud G et al (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920–925PubMedCrossRef
44.
Wong KK, Arabia M, Zerizerc I et al (2011) Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and non-fluorodeoxyglucose tracers. Nucl Med Commun 32:764–781PubMedCrossRef
45.
Leboulleux S, Deandreis D, Escourrou C et al (2011) Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol 164:89–94PubMedCrossRef
46.
Hennings J, Lindhe O, Bergstrom M et al (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91:1410–1414PubMedCrossRef
47.
Hahner S, Kreissl MC, Fassnacht M et al (2013) Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab 98:1508–1518PubMedCrossRef
48.
Kreissl MC, Schirbel A, Fassnacht M et al (2013) [123I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab 98:2755–2764PubMedCrossRef
49.
Tirabassi G, Kola B, Ferretti M et al (2012) Fine-needle aspiration cytology of adrenal masses: re-assessment with histological confirmation. J Endocrinol Invest 35:590–594PubMed
50.
Sasano H, Shizawa S, Suzuki T et al (1995) Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol 26:1154–1156PubMedCrossRef
51.
Sbiera S, Schmull S, Assie G et al (2010) High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 95:161–171CrossRef
52.
Sangoi AR, Fujiwara M, West RB et al (2011) Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol 5:678–686CrossRef
53.
Duregon E, Fassina A, Volante M et al (2013) The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation Study on 245 unpublished cases. Am J Surg Pathol 37:1433–1440PubMedCrossRef
54.
Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206PubMedCrossRef
55.
Tissier F, Aubert S, Leteurtre E et al (2012) Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol 36:1194–1201PubMedCrossRef
56.
Macfarlane DA (1958) Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty cases. Ann R Coll Surg Engl 109:613–618
57.
Bradley EL 3rd (1975) Primary and adjunctive therapy in carcinoma of the adrenal cortex. Surg Gynecol Obstet 141:507–516PubMed
58.
Sullivan M, Boileau M, Hodges CV (1978) Adrenal cortical carcinoma. J Urol 120:660–665PubMed
59.
Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Supplement 7):vii131–vii138
60.
Terzolo M, Ardito A, Zaggia B et al (2012) Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 42:521–525PubMedCrossRef
61.
Bourdeau I, Mackenzie-Feder J, Lacroix A (2013) Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes 20:192–197PubMedCrossRef
62.
Icard P, Chapuis Y, Andreassian B et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112:972–979PubMed
63.
Lee JE, Berger DH, el-Naggar AK et al (1995) Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118:1090–1098
64.
Delellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) Pathology and genetics of tumours of endocrine organs. IARC, Lyon
65.
Fassnacht M, Johanssen S, Quinkler M et al (2009) German adrenocortical carcinoma registry group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243–250PubMedCrossRef
66.
Lughezzani G, Sun M, Perrotte P et al (2010) The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: a North American validation. Eur J Cancer 46:713–719PubMedCrossRef
67.
Terzolo M, Daffara F, Ardito A et al (2014) Management of adrenal cancer: a 2013 update. J Endocrinol Invest 37:207–217PubMedCrossRef
68.
Morimoto R, Satoh F, Murakami O et al (2008) Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 55:49–55PubMedCrossRef
69.
van’t Sant HP, Bouvy ND, Kazemier G et al (2007) The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathol 51:239–245
70.
Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. New Engl Med 356:2372–2380CrossRef
71.
Volante M, Bollito E, Sperone P et al (2009) Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathol 55:535–543CrossRef
72.
Papotti M, Libè R, Duregon E et al (2011) The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm canc 2:333–340CrossRef
73.
van Slooten H, Schaberg A, Smeenk D et al (1985) Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55:766–773PubMedCrossRef
74.
Evans HL, Vassilopoulou-Sellin R (1996) Adrenal cortical neoplasms: a study of 56 cases. Am J Clin Pathol 105:76–86PubMed
75.
Stojadinovic A, Ghossein RA, Hoos A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941–950PubMedCrossRef
76.
Assie G, Antoni G, Tissier F et al (2007) Prognostic parameters of metastatic adrenocortic carcinoma. J Clin Endocrinol Metab 92:148–154PubMedCrossRef
77.
Aiba M, Fujibayashi M (2005) Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol 16:13–22PubMedCrossRef
78.
Giordano TJ (2011) The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol 35:471–473PubMedCrossRef
79.
Beuschlein F, Obracay J, Saeger W et al (2013) Prognostic value of histological markers in localized adrenocortical carcinoma after complete resection. Endocr Rev 34:23–29
80.
Beuschlein F, Weigel J, Saeger W et al (2015) Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100:841–849PubMedCrossRef
81.
Aubert S, Wacrenier A, Leroy X et al (2002) Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26:1612–1619PubMedCrossRef
82.
Didolkar MS, Bescher RA, Elias EG, Moore RH (1981) Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 47:2153–2161PubMedCrossRef
83.
Luton JP, Cerdas S, Billaud L et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195–1201PubMedCrossRef
84.
Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88:711–736PubMedCrossRef
85.
Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253- patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891–897PubMedCrossRef
86.
Favia G, Lumachi F, D’Amico DF (2001) Adrenocortical carcinoma: is prognosis different in nonfunctioning tumors? Results of surgical treatment in 31 patients. World J Surg 25:735–738PubMedCrossRef
87.
Abiven G, Coste J, Groussin L et al (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650–2655PubMedCrossRef
88.
Berruti A, Fassnacht M, Haak H et al (2014) Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 65:832–838PubMedCrossRef
89.
Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657–666PubMedCrossRef
90.
Ronchi CL, Sbiera S, Leich E et al (2012) Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab 97:2251–2260CrossRef
91.
Giordano TJ, Kuick R, Else T et al (2009) Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668–676PubMedPubMedCentralCrossRef
92.
Laurell C, Velázquez-Fernández D, Lindsten K et al (2009) Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol 161:141–152PubMedCrossRef
93.
de Reyniès A, Assié G, Rickman DS et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108–1115PubMedCrossRef
94.
Ragazzon B, Libé R, Gaujoux S et al (2010) Transcriptome analysis reveals that p53 and{beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 70:8276–8281PubMedCrossRef
95.
Ragazzon B, Assié G, Bertherat J (2011) Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer 18:15–27CrossRef
96.
Assié G, Guillaud-Bataille M, Ragazzon B et al (2010) The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends Endocrinol Metab 21:325–334PubMedCrossRef
97.
Fenske W, Völker HU, Adam P et al (2009) Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 1:919–928CrossRef
98.
Duregon E, Volante M, Giorcelli J et al (2013) Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol 44:822–828PubMedCrossRef
99.
Soon PS, Tacon LJ, Gill AJ et al (2009) miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 15:7684–7692PubMedCrossRef
100.
Chabre O, Libé R, Assie G et al (2013) Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer 20:579–594PubMed
101.
Pinzani P, Scatena C, Salvianti F et al (2013) Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. J Clin Endocrinol Metab 98:3731–3738PubMedCrossRef
102.
Assié G, Letouzé E, Fassnacht M et al (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46:607–20141PubMedCrossRef
103.
Donatini G, Caiazzo R, Do Cao C et al (2014) Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol 21:284–291PubMedCrossRef
104.
Fosså A, Røsok BI, Kazaryan AM et al (2013) Laparoscopic versus open surgery in stage I-III adrenocortical carcinoma—a retrospective comparison of 32 patients. Acta Oncol 52(8):1771–1777PubMedCrossRef
105.
Lombardi CP, Raffaelli M, De Crea C et al (2012) Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery 152:1158–1164PubMedCrossRef
106.
Bellantone R, Ferrante A, Boscherini et al (1997) Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122:1212–1218
107.
Schulick RD, Brennan MF (1999) Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6:719–726PubMedCrossRef
108.
109.
110.
Wängberg B, Khorram-Manesh A, Jansson S et al (2010) The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17:265–272PubMedCrossRef
111.
Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112:963–971PubMed
112.
Crucitti F, Bellantone R, Ferrante A et al (1996) The italian registry for adrenal cortical carcinoma: analysis of a multi-institutional series of 129 patients. Surgery 119:161–170PubMedCrossRef
113.
Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. End Relat Cancer 12:667–680CrossRef
114.
Fassnacht M, Johanssen S, Fenske W et al (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized center. J Clin Endocr Metab 95:4925–4932PubMedCrossRef
115.
Porpiglia F, Fiori C, Daffara F et al (2010) Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 57:873–878PubMedCrossRef
116.
Brix D, Allolio B, Fenske W et al (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609–615PubMedCrossRef
117.
Reibetanz J, Jurowich C, Erdogan I et al (2012) Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 25:363–369CrossRef
118.
Gaujoux S, Brennan MF (2012) Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 152:123–132PubMedCrossRef
119.
Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130–3136PubMedCrossRef
120.
Kemp CD, Ripley RT, Mathur A et al (2011) Pulmonary resection for metastatic adrenocortical carcinoma. Ann Thorac Surg 92:1195–1270PubMedCrossRef
121.
122.
Datrice NM, Langan RC, Ripley RT et al (2012) Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 105:709–713PubMedPubMedCentralCrossRef
123.
Erdogan I, Deutschbein T, Jurowich C et al (2013) The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocr Metab 98:181–191PubMedCrossRef
124.
Veytsman I, Nieman L, Fojo T (2009) Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 27:4619–4629PubMedPubMedCentralCrossRef
125.
Grubbs EG, Callender GG, Xing Y et al (2010) Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 17:263–270PubMedCrossRef
126.
Terzolo M, Baudin E, Ardito A et al (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical. Eur J Endocrinol 169:263–270PubMedCrossRef
127.
Volante M, Terzolo M, Fassnacht M et al (2012) Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res 18:3452–3461PubMedCrossRef
128.
Sabolch A, Feng M, Griffith K et al (2011) Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 80:1477–1484PubMedCrossRef
129.
Fassnacht M, Hahner S, Polat B et al (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501–4504PubMedCrossRef
130.
Habra MA, Ejaz S, Feng L et al (2013) A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98:192–197PubMedPubMedCentralCrossRef
131.
Polat B, Fassnacht M, Pfreundner L et al (2009) Radiotherapy in adrenocortical carcinoma. Cancer 115:2816–2823PubMedCrossRef
132.
Keskin S, Taş F, Vatansever S (2013) Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int 90:435–438PubMedCrossRef
133.
Khan TS, Imam H, Juhlin C et al (2000) Streptozocin and o, p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281–1287PubMedCrossRef
134.
Fujii Y, Kageyama Y, Kawakami S et al (2003) Successful long-term disease-free survival following multimodal treatments in a patients with a repeatedly recurrent refractory adrenal cortical carcinoma. Int J Urol 10:445–448PubMedCrossRef
135.
Touitou Y, Bogdan A, Luton JP (1978) Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o, p′-DDD for Cushing’s syndrome: evidence for the sites of action of the drug. J Ster Biochem 9:1217–1224CrossRef
136.
Lin CW, Chang YH, Pu HF (2012) Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicol 298:14–23CrossRef
137.
Lehmann TP, Wrzesinski T, Jagodzinski PP (2013) The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep 7:893–900PubMed
138.
Bergenstal DM, Hertz R, Lipsett MB, Moy RH (1960) Chemotherapy of adrenocortical cancer with o, p′-DDD. Ann Int Med 53:672–682CrossRef
139.
van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–53PubMedCrossRef
140.
Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p′DDD, o, p′DDA, and o, p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851PubMedCrossRef
141.
Kerkhofs TM, Baudin E, Terzolo M et al (2013) Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 98:4759–4767PubMedCrossRef
142.
Mauclère-Denost S, Leboulleux S, Borget I et al (2012) High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 166:261–268PubMedCrossRef
143.
van Erp NP, Guchelaar HJ, Ploeger BA et al (2011) Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 164:621–626PubMedCrossRef
144.
Kroiss M, Quinkler M, Lutz WK et al (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin End 75:585–591CrossRef
145.
Haak HR, Hermans J, van de Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951PubMedPubMedCentralCrossRef
146.
Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroetane (o, p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392PubMedCrossRef
147.
Baudin E, Leboulleux S, Al Ghuzlan A et al (2011) Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 6:363–371CrossRef
148.
Bates SE, Shieh CY, Mickley LA et al (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metabol 73:18–29CrossRef
149.
Bukowski RM, Wolfe M, Levine HS et al (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11:161–165PubMed
150.
Schteingart DE (2000) Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 33:1197–1200PubMedCrossRef
151.
Bonacci R, Gigliotti A, Baudin E et al (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Brit J Cancer 78:546–549PubMedPubMedCentralCrossRef
152.
Burgess MA, Legha SS, Sellin RV (1993) Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc Ann Soc Clin Oncol 12:188
153.
Williamson SK, Lew D, Miller GJ et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88:1159–1165PubMedCrossRef
154.
Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. New Engl J Med 366:2189–2197PubMedCrossRef
155.
Barlaskar FM, Hammer GD (2007) The molecular genetics of adrenocortical carcinoma. Rev End Metab Dis 8:343–348CrossRef
156.
Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrin Metab 94:204–212CrossRef
157.
Carden CP, Frentzas S, Langham M et al (2009) Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF- 1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol 27:3544
158.
Haluska P, Worden F, Olmos D et al (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chem Pharm 65:765–773CrossRef
159.
Fassnacht M, Berruti A, Baudin E et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double blind, randomized, phase 3 study. Lancet Oncology 16:426–435PubMedCrossRef
160.
Doghman M, El Wakil A, Cardinaudetal B (2010) Regulation of IGF-mTOR signalling by miRNA in childhood adrenocortical tumors. Canc Res 70:4666–4675CrossRef
161.
Naing A, Kurzrock R, Burger A et al (2011) Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17:6052–6060PubMedPubMedCentralCrossRef
162.
163.
Wortmann S, Quinkler M, Ritter C et al (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adreno-cortical carcinoma. Eur J Endocrinol 162:349–356PubMedCrossRef
164.
Chaco R, Tossen G, Loria FS, Chaco M (2005) Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol 23:1579–1580CrossRef
165.
Kroiss M, Quinkler M, Johanssen S et al (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97:3495–3503PubMedCrossRef
166.
Hong DS, Sebti SM, Newman RA et al (2009) Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15:7061–7068PubMedPubMedCentralCrossRef
167.
Butler C, Butler WM, Rizvi AA (2010) Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. End Pract 16:441–445CrossRef
168.
Berruti A, Sperone P, Ferrero A et al (2012) Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrin 166:451–458CrossRef
169.
Lee JO, Lee KW, Kim CJ et al (2009) Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol 39:183–185PubMedCrossRef
170.
Gangadhar TC, Cohen EEW, Wu K et al (2011) Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 17:1956–1963PubMedPubMedCentralCrossRef
171.
Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93:2057–2062PubMedCrossRef
172.
Samnotra V, Vassilopoulou-Sellin R, Fojo AT et al (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 27:15527
173.
Gross DJ, Munter G, Bitan M et al (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. End Related Canc 13:535–540CrossRef
174.
Adam P, Hahner S, Hartmann M et al (2010) Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol 23:1596–1604PubMedCrossRef
175.
Abraham J, Bakke S, Rutt A et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333–2343PubMedCrossRef
176.
Papewalis C, Fassnacht M, Willenberg HS et al (2006) Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin Endocrinol 65:215–222CrossRef
177.
Wood BJ, Abraham J, Hvizda JL et al (2003) Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97:554–560PubMedPubMedCentralCrossRef
178.
Mayo-Smith WW, Dupuy DE (2004) Adrenal neoplasms: CT-guided radiofrequency ablation: preliminary results. Radiology 231:225–230PubMedCrossRef
179.
Tranberg KG (2004) Percutaneous ablation of liver tumours. Best Pract Res Clin Gastroenterol 18:125–145PubMedCrossRef
180.
Cazejust J, De Baere T, Auperin A et al (2010) Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 21:1527–1532PubMedCrossRef
Metadaten
Titel
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)
verfasst von
A. Stigliano
I. Chiodini
R. Giordano
A. Faggiano
L. Canu
S. Della Casa
P. Loli
M. Luconi
F. Mantero
M. Terzolo
Publikationsdatum
01.01.2016
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 1/2016
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0349-9

Weitere Artikel der Ausgabe 1/2016

Journal of Endocrinological Investigation 1/2016 Zur Ausgabe

Original Article

Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation

Endocrinology and Art

Maddalena Ventura: an impressive case of hirsutism in a painting of Jusepe De Ribera (1631)

Review

Neuroprotective effects of estrogens: the role of cholesterol

Review

Growth hormone insensitivity: diagnostic and therapeutic approaches

Original Article

Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital

Original Article

The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise